Kisqali

(ribociclib)
ribociclib 200 MG Oral Tablet [Kisqali]
NO BOXED WARNING

Dosage & administration

KISQALI tablets are taken orally with or without food in combination with an aromatase inhibitor or fulvestrant.

drug label

Kisqali prescribing information

prior authorization

Kisqali prior authorization resources

Most recent Kisqali prior authorization forms

View By Payer
Verified: Feb 07, 2024Kaiser Foundation Health Plan - Chronic High-Dose Opioid Therapy Prior Authorization Form Washington
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Medical Injectable Specialty Drug Prior Authorization Form
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Outpatient Chemotherapy Prior Authorization Form (Medical Benefit)
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Specialty Drug Prior Authorization Form
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Non-Formulary Drug Coverage Prior Authorization Form

Most recent state uniform prior authorization forms

Verified: Jan 28, 2024Oregon - Uniform Prior Authorization Form
Verified: Jan 28, 2024Colorado - Uniform Prior Authorization Form
Verified: Jan 28, 2024Michigan - Uniform Prior Authorization Form
Verified: Jan 28, 2024Hawaii - Uniform Prior Authorization Form
Verified: Jan 28, 2024Minnesota - Uniform Prior Authorization Form
Verified: Jan 28, 2024New Hampshire - Uniform Prior Authorization Form
Verified: Jan 28, 2024New Mexico - Uniform Prior Authorization Form
Verified: Jan 28, 2024Texas - Uniform Prior Authorization Form
Verified: Jan 28, 2024Louisiana - Uniform Prior Authorization Form
Verified: Jan 28, 2024Arizona - Uniform Prior Authorization Form
Verified: Jan 28, 2024Indiana - Uniform Prior Authorization Form
Verified: Jan 28, 2024Illinois - Uniform Prior Authorization Form
Learn More

Benefits investigation

PANO Service Request Form - Patient
PANO Service Request Form - HCP
Learn More

Financial Assistance

Financial Assistance Programs

Kisqali retails for $15,162 per dose without insurance or financial assistance.Depending on your patient's insurance situation and other eligibility criteria, they may be able to get Kisqali for significantly less. Review the program information below to determine what program can offer your patient the most benefits.
CoPay Card Program$0 Co Pay
Available for
commercial
Program Details
  • $15162 for Month
  • $15000 Annual Cap
Forms
Enroll in Patient Savings Porgam - Kisqali
Enroll in Patient Savings Program - Kisqali Femara Copack
Foundation ProgramFirst dose for $0
Available for
uninsured
Eligibility requirements
  • Uninsured
  • Household annual adjusted gross income <= % FPL.
Forms
PANO Service Request Form - Patient
PANO Service Request Form - HCP

PubMed™ | Kisqali

Kisqali PubMed™ News

patient education

Kisqali patient education

To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link

Patient toolkit

Managing Your Day-To-Day Resources
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Doctor Discussion Guide
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
About Kisqali
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
View How to Take Kisqali
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Side Effects
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Managing Side Effects
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Stories
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Monitoring Your Treatment
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

people also ask

Kisqali FAQs

Is it safe to take KISQALI during pregnancy?No, KISQALI can cause fetal harm when administered to a pregnant woman based on findings from animal studies and the mechanism of action. The background risk of major birth defects and miscarriage for the indicated population is unknown. Pregnant women should be advised of the potential risk to a fetus.
Can KISQALI be taken while breastfeeding?It is not known if ribociclib, the active ingredient in KISQALI, is present in human milk. Ribociclib and its metabolites readily passed into the milk of lactating rats. Lactating women are advised not to breastfeed while taking KISQALI and for at least 3 weeks after the last dose.
Should females of reproductive potential take any precautions while taking KISQALI?Females of reproductive potential should undergo pregnancy testing prior to starting treatment with KISQALI. Effective contraception methods that result in less than 1% pregnancy rates are recommended during treatment with KISQALI and for at least 3 weeks after the last dose.
Can KISQALI be used in pediatric patients?No, the safety and efficacy of KISQALI in pediatric patients has not been established.
Can KISQALI be used in geriatric patients?No overall differences in safety or effectiveness of KISQALI were observed between geriatric patients (≥65 years old) and younger patients in clinical studies.
Are there any dosage adjustments required for patients with hepatic impairment?No dose adjustment is necessary for patients with mild hepatic impairment (Child-Pugh class A). A reduced starting dose of 400 mg is recommended for patients with moderate (Child-Pugh class B) and severe hepatic impairment (Child-Pugh class C).
Are there any dosage adjustments required for patients with renal impairment?No dose adjustment is necessary for patients with mild or moderate renal impairment. For patients with severe renal impairment (eGFR 15 to < 30 mL/min/1.73 m2), a starting dose of 200 mg is recommended based on a renal impairment study in healthy subjects and non-cancer subjects.
FAQ Data Source